story of the week
BMI-Related Differential Benefit of Adjuvant Docetaxel in Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index
J. Clin. Oncol 2020 Jul 02;[EPub Ahead of Print], C Desmedt, M Fornili, F Clatot, R Demicheli, D De Bortoli, A Di Leo, G Viale, E de Azambuja, J Crown, PA Francis, C Sotiriou, M Piccart, E BiganzoliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.